Member Info for reef13

BOOM now No1 audio and video publisher in the world, overtaking Spotify and all the others, according to latest Podscribe rankings.

Well, some A***hole got my previous post removed. Clearly someone doesn’t want you to know the good news. Amazing how these loons let derampers operate with impunity, but anyone trying to post positive news gets censored. I’ve been buying all morning, when it wasn’t going to NT! Decks cleared for a good run now. Easy bagger.

I’m told by my broker that the seller is cleared. This is now a stonking buy and an easy bagger in my view.

Let’s consider the facts:

1) Rosen (79m shares) and likely Candy have tens of millions of pounds already tied up in AAA, plus £100m worth of options at 50p.

2) Another UHNW individual bought £2.4m at 63p a couple of weeks ago.

3) “AAQUA will launch in Asia later this year. It is a social media platform, backed by an as yet unnamed global technology company”

4) Recent appointments include ex-Barclays/Sky as an NED; ex-Facebook/McKinsey Exec as a Board Advisor and Managing Director; ex-Tech/Innovation at Sky/Telefonica as a Managing Director.

So, the detractors are asking you to believe that all these wealthy and successful businessmen are going to lose all their money and professional reputations, and that they, along with a global technology company, are part of a giant, self-harming scam, which actually causes they themselves to lose millions.

The desperate rantings of spiteful, jealous and likely short selling idiots.

Hopefully extremely positive news in the pipe, and would be the icing on the cherry on the cake if TWat and Hogan were still locked in short! ??

Winnifrith and Hogan. Allegedly.

I just got blocked by Align Research (Jennings) for calling them out, which suggests more than a grain of truth. Other suspects include Pizza Man and The Welsh Nonce.

Common knowledge that this is a coordinated shorting attack by well know liars and disinformation specialists. Short and distort.

When they realise who they’re up against and the big guns are wheeled out, there’ll be one almighty short squeeze. I will take great pleasure in watching them burn.

Well DVR still thinks there’s value here even at this level! Good enough for me!

Indeed. I spoke to a broker yesterday and asked him if any “large holders” were “cashing out”. His answer was, once he’d stopped laughing, “to the best of my knowledge, no.....on the contrary in fact”.

Make of that what you will.

Heading for 20p.

I don’t believe so. The previous poster has joined this week with the sole purpose of discrediting Akers and these deals. His information is incorrect and misleading. Sentiance was featured by Deloitte in their fastest growing tech companies report and has revenues estimated at $5m, although nobody is privy to the actual number as they are a private company. Let’s just wait and see how this all plays out.

Correct, it’s 100% a buy. Something clearly happening in the background here.

Anyone planning to attend tomorrow?

Response from David Smith to the questions raised by Elartu: Thanks for the question. I’ve seen this a number of times and it comes from a fundamental misunderstanding of how the 510k system works. First of all, the easy part, the lack of TexRad IP is irrelevant as far as FDA goes. The 510k system requires you to nominate a ‘predicate’ , or preceding device that also has a 510k to which you will compare your product. All that you need to do is to demonstrate safety and efficacy. Safety is normally demonstrated by showing that you produce your device to the ISO standards (usually ISO 13485) in a validated Quality System. Efficacy is demonstrated by comparing the performance of your device to something that is already on the market. In this case we demonstrated against an array of products, since there is nothing quite like the StoneChecker software. We submitted a package that we believe demonstrates that the product can reliably predict the likelihood that sound waves will break up the kidney stone during a lithotripsy procedure by using data from a few hundred patients who had undergone lithotripsy. The presence or absence of TexRad is a bit of a red herring. Let me give you an analogy. Let’s say we were trying to get a 510k for a new type of electronic thermometer. We would probably choose an old fashioned mercury thermometer to compare - our predicate device. We would simply run bench tests to show that the temperatures measured by the electronic thermometer matches those recorded by the mercury filled thermometer. It would be irrelevant that the electronic thermometer featured a Samsung thermistor (TexRad), or that it had IP coverage, since the real magic in this case would be the way we used the thermistor, and our proprietary software, not the thermistor. In fact, this would give us an advantage since we could always substitute out a different thermistor if we later found one that performed equally well for less money. In summary we believe we are well placed to be cleared for marketing before the end of the year. Our package was accepted by FDA on August 22.

Care to post any evidence to support your assertions?

Just a few words of thanks to EB and SmudgeDan, who have maintained my faith in this share through their excellent research and in the face of some of the most ignorant and uninformed rubbish I've ever seen posted on a BB from Radar. I truly hope that individual is feeling thoroughly sick this morning and that this may teach them a valuable lesson. Over to you, Harry Stratford, time to do something spectacular this time.